6 results about "Bacteroides salyersiae" patented technology

This invention, entitled "A Composition Containing Pentadecanoic Acid, Parabacterium Species Outer Membrane Vesicles Containing the Composition, and Their Applications," belongs to the field of probiotics and microbial preparations technology. The technical problem this invention aims to solve is that beneficial live bacteria have weak colonization ability in the gut, are easily affected by the gastrointestinal environment, exhibit unstable individual responses, and struggle to simultaneously address immune regulation and barrier repair. This invention provides a composition containing pentadecanoic acid, Parabacterium Species-derived outer membrane vesicles, and their applications. The outer membrane vesicles are derived from *Parabacterium difficile* and are rich in pentadecanoic acid, palmitic acid, and octadecanoic acid. The composition and outer membrane vesicles prepared by this invention can significantly inhibit macrophage M1 polarization and reduce pro-inflammatory cytokines. TNF-α , IL-6 and IL-1 β It can lower the expression level of [something], reduce intracellular reactive oxygen species levels, improve mitochondrial function, significantly alleviate symptoms of colitis induced by sodium dextran sulfate, regulate the intestinal flora structure, and increase the abundance of beneficial bacteria.

This invention belongs to the field of intestinal microbiome technology, and particularly relates to the application of a capsular polysaccharide derived from Bacteroides Salilsii CSP6 in the treatment and / or prevention of inflammatory bowel disease. The Bacteroides Salilsii strain is... Bacteroides salyersiae CSP6. This strain was isolated from the intestine of healthy humans and deposited at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M 20221993. In vivo experiments showed that the capsular polysaccharide derived from Bacteroides Salieris CSP6 can protect the colorectal mucosa from damage and promote the repair of damaged intestinal mucosa, thereby improving symptoms such as loose stools, rectal bleeding, and shortened colon and rectum, reducing weight loss caused by intestinal damage and inflammation, and ultimately exerting a therapeutic effect on inflammatory bowel disease.

This invention discloses a monoclonal antibody against a Bacteroides fragilis-specific protein and its applications, belonging to the field of biotechnology. Using the OmpA and SusD proteins on the surface of Bacteroides fragilis as immunogens, this invention prepares a highly specific monoclonal antibody with strong antigen-binding affinity using hybridoma technology. After conjugating this monoclonal antibody with magnetic beads, the resulting magnetic bead antibody conjugate can efficiently enrich and / or isolate Bacteroides fragilis from treated samples, offering advantages of convenience and low cost. Furthermore, the isolated Bacteroides fragilis can be used for whole-genome sequencing, metabolite analysis, and strain function research, providing new technical means for Bacteroides fragilis microecological research, probiotic preparation quality control, rapid clinical diagnosis, and functional strain screening.

The application discloses an adult depression intestinal microorganism marker and application thereof, and belongs to the field of biological medicine. The microorganism marker comprises one or more of the following: Clostridium aldrichii, Coprococcus comes, Klebsiella pneumoniae, Bifidobacterium adolescentis, Bacteroides vulgatus, Eubacterium eligens and Faecalibacterium prausnitzii. The application provides a product (such as a kit) comprising detection reagents for detecting the relative abundance of the microorganism marker. The product provided by the application has good feasibility and accuracy, and can effectively evaluate the risk of whether an adult has depression, thereby providing a new tool for clinical diagnosis.

The application discloses a private part care spray capable of balancing private part microecology, removing peculiar smell, killing bacteria and resisting viruses, and belongs to the technical field of private part care and disinfection materials. The private part care spray is prepared by compounding 3.8-6.5 parts of a modified edible bactericide, 3.2-5.5 parts of food-grade lactic acid, 2.2-3.0 parts of modified food-grade gentian root extract and the rest food-grade deionized water. The activity and stability of raw materials are improved through the processes of β-cyclodextrin inclusion modification of the bactericide and compounding of the modified product with the modified food-grade gentian root extract. The product has a killing rate of 99.9% on Neisseria gonorrhoeae, Gardnerella vaginalis, Bacteroides, Streptococcus pyogenes, Candida albicans, Staphylococcus epidermidis, Escherichia coli and Pseudomonas aeruginosa, an inactivation rate of 99.99% on herpes simplex virus SHV-2 and HPV16 virus, an ammonia removal rate of 95%, a peculiar smell inhibition duration of 48 h and a mucous membrane irritation level of 0, and the preparation process is simple and suitable for industrial production.

This invention belongs to the field of biotechnology, specifically relating to an antimicrobial peptide for improving intestinal health and combating diarrhea in animals, and its preparation method. The invention prepares a novel antimicrobial peptide with the amino acid sequence shown in SEQ ID NO:1. Experiments have verified that after one week of feeding in an unfamiliar environment, the antimicrobial peptide can slightly increase the levels of propionic acid and butyric acid in the experimental group of cats. Furthermore, the overall BCFAs levels in the experimental group were lower than those in the control group before and after transportation. Although there were no significant differences in α-diversity and β-diversity between the experimental group fed the antimicrobial peptide and the control group, feeding the antimicrobial peptide significantly increased the levels of Bacteroides, Parabacterium, and Prevotella in the experimental group, and significantly reduced the levels of harmful bacteria Salmonella and Actinomyces. Therefore, the antimicrobial peptide of this invention can be used to prepare products for improving intestinal health and combating diarrhea in animals, such as feed additives or oral liquids.